These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26769920)

  • 1. Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors.
    Shi X; Lin X; Hu R; Sun N; Hao J; Gao C
    Am J Alzheimers Dis Other Demen; 2016 Aug; 31(5):405-12. PubMed ID: 26769920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
    Standridge JB
    Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Alzheimer's disease in the long-term-care setting.
    Smith DA
    Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].
    Yamada M
    Brain Nerve; 2023 May; 75(5):464-469. PubMed ID: 37194514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
    Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationalizing therapeutic approaches in Alzheimer's disease.
    Grossberg GT
    CNS Spectr; 2005 Nov; 10(11 Suppl 18):17-21. PubMed ID: 16273026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.
    Lampela P; Tolppanen AM; Tanskanen A; Tiihonen J; Lavikainen P; Hartikainen S; Taipale H
    Ann Med; 2017 May; 49(3):230-239. PubMed ID: 27786552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
    Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
    Thompson S; Lanctôt KL; Herrmann N
    Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the rationale for new treatment strategies in Alzheimer's disease?
    Rogawski MA
    CNS Spectr; 2004 Jul; 9(7 Suppl 5):6-12. PubMed ID: 15241294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.
    Kennedy RE; Cutter GR; Fowler ME; Schneider LS
    JAMA Netw Open; 2018 Nov; 1(7):e184080. PubMed ID: 30646339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
    Farlow MR
    Geriatrics; 2004 Jun; 59(6):22-7. PubMed ID: 15224791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.
    Lopez OL; Becker JT; Wahed AS; Saxton J; Sweet RA; Wolk DA; Klunk W; Dekosky ST
    J Neurol Neurosurg Psychiatry; 2009 Jun; 80(6):600-7. PubMed ID: 19204022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].
    Schölzel-Dorenbos CJ;
    Tijdschr Gerontol Geriatr; 2005 Jul; 36(3):122-6. PubMed ID: 16078659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
    Deardorff WJ; Grossberg GT
    Expert Opin Pharmacother; 2016 Sep; 17(13):1789-800. PubMed ID: 27450461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.